2023 Annual Report to Shareholders
Enjoyed this read?
Stay up to date with our latest research.
BACK TO NEWS
Related articles
Press Releases and Media
A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US
PR Newswire • July 22, 2025
Press Releases and Media
FIVEAA Adelaide radio interview with Dr Steven Gourlay on once-a-day Alzheimer’s pill [8m 25s]
FIVEAA • July 1, 2025